Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTANIL vs ALA-SCALP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Treatment of minimally to moderately thick actinic keratoses of the scalp (Grade 1 or 2) in immunocompetent patients,Off-label: other photosensitivity disorders
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Topical application of a 5% solution to the scalp twice daily.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
ALA is metabolized intracellularly via the heme biosynthesis pathway to protoporphyrin IX (Pp IX).
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Not characterized; systemic levels are negligible after topical administration.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Not applicable for topical route. If systemic exposure occurs, Vd is approximately 0.5 L/kg, consistent with distribution into total body water.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
Topical: Systemic bioavailability is minimal (<1%) due to poor percutaneous absorption and rapid local metabolism.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
No dose adjustment required for renal impairment.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
No dose adjustment required for hepatic impairment.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Safety and efficacy in pediatric patients have not been established.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
No specific dose adjustment recommended; use with caution due to potential increased sensitivity.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
No FDA black box warning.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Photosensitivity: avoid exposure to sunlight or bright indoor light (e.g., examination lamps, operating room lamps) for at least 40 hours post-application.,Application site reactions: severe stinging, burning, erythema, and edema may occur.,Use sun-protective measures (e.g., wide-brimmed hat, sunscreen) after treatment.,Do not apply to eyes or mucous membranes.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Hypersensitivity to aminolevulinic acid or any component of the formulation,Cutaneous photosensitivity at wavelengths of 400-450 nm,Porphyria
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
No known food interactions. No dietary restrictions required.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Minimal systemic absorption; unlikely to appear in breast milk. M/P ratio not established. Considered compatible with breastfeeding.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
No dosage adjustment required; pharmacokinetics unlikely altered due to topical route.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
ALA-SCALP is a topical aminolevulinic acid preparation used for photodynamic therapy of actinic keratoses on the scalp. Must be applied by a healthcare professional. Avoid sun exposure to treated area for 48 hours post-application due to photosensitivity. Do not apply to eyes or mucous membranes. Lesions should be prepped by gentle removal of scales and crusts. Use with a compatible light source (blue light). Burning and stinging during light exposure is common; consider pain management strategies.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
This medication is applied by your doctor to treat precancerous spots on your scalp.,After application, you will need a special light treatment (photodynamic therapy).,Avoid sunlight and bright indoor light on the treated area for 48 hours after the procedure.,You may experience temporary redness, swelling, scaling, or discomfort at the treatment site.,Use sunscreen and protective clothing when going outdoors during the photosensitivity period.,Do not wash the treated area for at least 4 hours after the solution is applied.,Contact your doctor if you experience severe pain, blistering, or signs of infection.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTANIL vs ALA-SCALP, answered by our medical review team.
ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. ALA-SCALP is a Topical Corticosteroid that works by ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTANIL and ALA-SCALP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. The standard adult dose of ALA-SCALP is: Topical application of a 5% solution to the scalp twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTANIL and ALA-SCALP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. ALA-SCALP is classified as Category C. No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.